Form 4: Matinas BioPharma Director Robin L. Smith Acquires Stock Options

Director Robin L. Smith reports acquisition of stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Summary

• Robin L. Smith, a director of Matinas BioPharma Holdings, Inc., reported the acquisition of stock options.
• The transaction occurred on April 30, 2025.
• Smith acquired 11,600 stock options with an exercise price of $0.59.
• These options are subject to the approval of the Issuer's 2025 Equity Incentive Plan.
• The 2025 Plan will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025.
• 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.
• The options expire on April 30, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction; positive if the market interprets it as confidence from the director, negative if the equity plan is seen as dilutive.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting of the options is contingent upon stockholder approval of the 2025 Equity Incentive Plan; failure to obtain approval would impact the director's compensation.

Future Outlook

The vesting of the options is dependent on the approval of the 2025 Equity Incentive Plan at the upcoming stockholder meeting.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price would need to be compared to similar grants at peer companies to assess competitiveness.
• Companies like Amgen, Gilead, and Biogen often use stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders: Potential dilution if the options are exercised.
• Employees: May be affected by the overall equity incentive plan.
• Director: Robin L. Smith is directly impacted by the vesting of the options.

Next Steps

• Stockholder vote on the 2025 Equity Incentive Plan at the annual meeting on June 23, 2025.
• Vesting of the options on April 30, 2026, contingent upon stockholder approval.

Key Dates

Keywords

stock options, Matinas BioPharma, director, Robin L. Smith, equity incentive plan, MTNB